In February 2025, Integrum presented its new strategy for accelerating the commercialization of OPRA® Implant System. Since then, the company has successfully strengthened its partnerships with leading Centers of Excellence in the US and key European markets, enhanced its post-market work around Axor II, and established a more sustainable cost base better suited for profitable growth. The changes announced today aim to further optimize the organization and enable a more efficient approach to market development.

"To further scale up sales in the US, we now need to put full focus on identifying the patients who can benefit from our innovative implant system and guide them to our Centers of Excellence. This requires a somewhat different organization that is more focused on the patient journey and digitalization. There is significant potential here, motivation within the organization is high, and I will personally increase my presence in the US to drive this work forward. At the same time, we see opportunities to further streamline our global production and supply chain, with our new Chief Supply Chain Officer, Per Nilsson, playing a key role. I am also pleased that Dr. Rickard Brånemark is taking on an operational position where Integrum can fully leverage his unique expertise and ability to spread knowledge about osseointegration and the future of prosthetic surgery," says Martin Hillsten, CEO of Integrum.

Following the organizational changes, Integrum's management team consists of Martin Hillsten, Chief Executive Officer, Louise Wåhlin, Chief Financial Officer, Dr. Annika Fahlén, Director of Quality Assurance and Regulatory affairs, Dr. Rickard Brånemark, Chief Medical and Scientific Officer, and Per Nilsson, Chief Supply Chain Officer (assuming the role on March 16).